Literature DB >> 11468940

Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.

K G Kowalski1, M M Hutmacher.   

Abstract

We propose an efficient algorithm for screening covariates in population model building using Wald's approximation to the likelihood ratio test (LRT) statistic in conjunction with Schwarz's Bayesian criterion. The algorithm can be applied to a full model fit of k covariate parameters to calculate the approximate LRT for all 2k - 1 possible restricted models. The algorithm's efficiency also permits internal validation of the model selection process via bootstrap methods. We illustrate the use of this algorithm for both model selection and validation with data from a Daypro pediatric study. The algorithm is easily implemented using standard statistical software such as SAS/IML and S-Plus. A SAS/IML macro to perform the algorithm is provided.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468940     DOI: 10.1023/a:1011579109640

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  3 in total

1.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Automated covariate model building within NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

3.  Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.

Authors:  A Karim
Journal:  J Clin Pharmacol       Date:  1996-11       Impact factor: 3.126

  3 in total
  32 in total

1.  Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Authors:  Ying Hong; Kenneth G Kowalski; Jenny Zhang; Li Zhu; Mariaarantxa Horga; Richard Bertz; Marc Pfister; Amit Roy
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Journal:  AAPS PharmSci       Date:  2002

Review 3.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

Review 4.  On some "disadvantages" of the population approach.

Authors:  Jerry R Nedelman
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

5.  A genetic algorithm-based, hybrid machine learning approach to model selection.

Authors:  Robert R Bies; Matthew F Muldoon; Bruce G Pollock; Steven Manuck; Gwenn Smith; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-28       Impact factor: 2.745

6.  Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

Authors:  H Schmidli; B Peng; G-J Riviere; R Capdeville; M Hensley; I Gathmann; A E Bolton; A Racine-Poon
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

7.  Informative study designs to identify true parameter-covariate relationships.

Authors:  Phey Yen Han; Carl M J Kirkpatrick; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-03-27       Impact factor: 2.745

8.  The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.

Authors:  Karin Tunblad; Lars Lindbom; Lynn McFadyen; E Niclas Jonsson; Scott Marshall; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-11-15       Impact factor: 2.745

9.  A fast method for testing covariates in population PK/PD Models.

Authors:  Akash Khandelwal; Kajsa Harling; E Niclas Jonsson; Andrew C Hooker; Mats O Karlsson
Journal:  AAPS J       Date:  2011-07-02       Impact factor: 4.009

Review 10.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.